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OBJECTIVES The aim of this study was to determine the prevalence of cardiovascular dysfunction and its
predictors in children with acquired immunodeficiency syndrome (AIDS).
BACKGROUND Cardiovascular manifestations are common among children with AIDS but may be clinically
occult.
METHODS We reviewed the medical records, echocardiograms, electrocardiograms, and Holter monitor
studies of 68 children with AIDS. We tested clinical and demographic characteristics at the
time of AIDS diagnosis for their ability to predict serious cardiac events, death, and cardiac
death.
RESULTS The median time from AIDS diagnosis to death or end of follow-up was 1.0 year (range, 1
week to 7.9 years). Nineteen patients (28%) experienced serious cardiac events after AIDS
diagnosis. Of 43 patients who died, 15 (35%) had cardiac dysfunction. Multivariable analyses
revealed that recurrent bacterial infections, wasting, encephalopathy, male gender, and an
earlier year of AIDS diagnosis were predictors of serious cardiac events (relative risk [RR] 
9.3, 6.9, 4.7, 4.1, and 0.76, respectively, p  0.05). Wasting, encephalopathy, a low
age-adjusted CD4 count, a low age-adjusted immunoglobulin G (IgG) level, and an earlier
year of AIDS diagnosis increased the risk of all-cause mortality (RR 8.9, 5.1, 2.7, 0.82, and
0.8, respectively, p  0.02). Male gender, a low age-adjusted CD4 count, and a low
age-adjusted IgG level increased the risk for cardiac death (RR  16.9, 4.2, and 0.68,
respectively, p  0.05).
CONCLUSIONS Serious cardiac events and cardiac death are common among children with AIDS. Factors
such as recurrent bacterial infections, wasting, encephalopathy, male gender, low CD4 and
IgG levels, and an earlier year at AIDS diagnosis may identify high-risk patients. (J Am Coll
Cardiol 2003;41:1598–605) © 2003 by the American College of Cardiology Foundation
Cardiac manifestations of human immunodeficiency virus
(HIV) infection in children are protean and common (1,2).
They include asymptomatic and symptomatic cardiac dys-
function, hemodynamic abnormalities, dysrhythmias, car-
diac arrest, and cardiac death (1–11). These abnormalities
occur frequently as the prevalence of HIV infection among
children is high and as advances in therapy and management
improve life expectancy. More than 90% of the estimated
1,700 new pediatric HIV infections that occur each day
around the world occur in developing countries (12). The
ability to identify patients at particularly high risk for
cardiovascular abnormalities would improve care because
care of HIV-infected patients relies on accurate diagnosis
and prompt management of underlying illnesses, including
symptomatic cardiac diseases (13).
In previous work, we focused on different stages of HIV
disease (1,5,6,10). Those studies were not restricted to
predictors at the time of acquired immunodeficiency syn-
drome (AIDS) diagnosis, as performed in this report.
In studies of HIV-infected children, adverse cardiac
events were more frequent and severe in children with
advanced HIV disease (1,5,8,10). The risk of most adverse
cardiac outcomes was higher in children with AIDS-
defining conditions (except for those with lymphoid inter-
stitial pneumonitis [LIP]) than in HIV-infected children
without AIDS (1). We therefore studied AIDS patients to
identify predictors at the time of the first AIDS-defining
illness that could identify patients at high risk for subse-
quent cardiac morbidity and mortality. We focused on
predictors that are commonly recorded and involve safe,
simple, and inexpensive regimens so that the study results
would be relevant in all settings in the U.S. and also in
countries with less developed health systems.
METHODS
Patient selection. The eligible population consisted of 87
children infected with HIV who met the Centers for
Disease Control and Prevention (CDC) criteria for AIDS
(14) and who were followed at Children’s Hospital, Boston
from January 1984 through June 1994. Thirteen patients
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were excluded because they were enrolled in a National
Institutes of Health study of heart and lung complications of
pediatric HIV infection that restricted the use of study data;
four were excluded because they had been diagnosed with
AIDS at another institution; and two were excluded because
their medical records were unavailable. All of the remaining
68 patients (78% of those eligible) were included.
Cardiac studies. Echocardiograms, electrocardiogram
(ECGs), or 24-h continuous ambulatory electrocardiographic
monitoring studies (Holter studies) were performed.
Of 309 echocardiograms from 61 patients (median, 5
studies per patient; range 1 to 18 studies per patient), 278
included a complete assessment of left ventricular fractional
shortening. The remaining 31 studies were limited to a
qualitative or subjective assessment of left ventricular sys-
tolic performance. During all echocardiographic studies, a
Dinamap automated vital signs monitor (Critikon Inc.,
Tampa, Florida) was used to monitor heart rate and blood
pressure (median, 5 min) while the child was in the relaxed
state or, for children under age 2, while the child was
sedated with chloral hydrate. Left ventricular fractional
shortening was calculated as previously reported (3,15–17).
Sixty-two patients had 262 ECG studies (median, 3 studies
per patient; range, 1 to 16 studies per patient). Thirty-six
patients had 24-h electrocardiographic Holter monitoring
(80 studies; median, 2 studies per patient; range, 1 to 10
studies per patient). The ECGs were evaluated using
standard criteria (18,19).
Medical record review. Inpatient and outpatient medical
records were reviewed by unmasked pediatric physicians
who recorded information about the potential clinical pre-
dictors at the time of AIDS diagnosis and who looked for
documented abnormalities in heart rate, blood pressure, and
heart rhythm. Potential clinical predictors for which data
were collected included demographics, mode of acquisition
of HIV, AIDS classification, co-infection with Epstein-
Barr virus (EBV) and cytomegalovirus (CMV), CD4 cell
count, serum immunoglobulin levels, antiretroviral therapy,
and history of cardiac abnormalities. Approval for this
medical record review was obtained from the Committee on
Human Investigation at Children’s Hospital, Boston.
Definition of clinical predictors. AIDS CLASSIFICATION.
The AIDS-defining illnesses were classified according to
the 1987 CDC classification system for children that was
being used at the time the study children were diagnosed
with AIDS (14). These illnesses were encephalopathy (P-
2B), LIP (P-2C), opportunistic infections (P-2D1), severe
recurrent bacterial infections (P-2D2), secondary cancer
(P-2E1), and wasting.
EBV AND CMV STATUS. Coinfection with EBV was deter-
mined by the presence of serum immunoglobulin G (IgG)
antibody to EBV capsid antigen measured by immunoflu-
orescence (20,21). Co-infection with CMV was determined
by the presence of serum IgG antibody to CMV measured
by enzyme-linked immunosorbent assay (22), or by cultur-
ing the virus in urine (by the spin-enhanced technique or by
growth in human diploid fibroblast cells) (23). Seropositive
test results for EBV and CMV were not considered evi-
dence of infection if they were obtained in infants under 12
months old because persistent maternal antibody may have
confounded a serologic diagnosis. Similarly, seropositive test
results for EBV and CMV were excluded if the tests were
performed within three months after intravenous immuno-
globulin therapy.
T-CELL LYMPHOCYTE COUNT. CD4 and CD8 cell counts
were performed within three months after AIDS diagnosis
using standard flow cytometry (FACScan, Becton Dickin-
son, San Jose, California) after whole-blood lysis. Normal
age-related changes in absolute CD4 counts were adjusted
by computing a z-score for each subject using the means and
standard deviations for age in normal healthy children. The
standards used were those generated by Mofenson et al. (24)
from CD4 lymphocyte counts reported in normal children
in nine published reports. The z-score is the difference
between the child’s CD4 count and the count predicted
from the reference standard for age, divided by the standard
deviation.
IMMUNOGLOBULINS. Serum levels of IgG, immunoglobu-
lin A, and immunoglobulin M (IgM) were determined
within three months after AIDS diagnosis by nephelometry
and electroimmunoassay. No child in this database was
receiving intravenous IgG at the time of baseline data
collection. The immunoglobulin levels were standardized
for age by creating z-scores from the published means and
standard deviations from 201 normal children (25). We
used polynomial regression against age to smooth the mean
immunoglobulin levels as reported by Buckley et al. (25).
Similar polynomial regression models were used to smooth
the upper and lower confidence bounds (25). Z-scores for
each child in our cohort were then calculated by subtracting
the smoothed age-adjusted mean and dividing by the
smoothed age-adjusted standard deviation.
HEMOGLOBIN, ANEMIA, AND ALBUMIN. Anemia was de-
fined as a hemoglobin level below 8 g/dl. Serum albumin
levels were used as continuous measures.
Abbreviations and Acronyms
AIDS  acquired immunodeficiency syndrome
CDC  Centers for Disease Control and Prevention
CMV  cytomegalovirus
DDC  dideoxycytosine
DDI  dideoxyinosine
EBV  Epstein-Barr virus
ECG  electrocardiogram
HIV  human immunodeficiency virus
IgG  immunoglobulin G
IgM  immunoglobulin M
LIP  lymphoid interstitial pneumonitis
RR  relative risk
ZDV  zidovudine
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HEIGHT AND WEIGHT. Height and weight were adjusted
for age and gender using the National Center for Health
Statistics norms (26) and were expressed as z-scores. Wast-
ing was defined according to the 1987 CDC classification
system for children (14).
ANTIRETROVIRAL THERAPY. Patients were categorized as
having received antiretroviral therapy if they had been on
zidovudine (ZDV), dideoxyinosine (DDI), or dideoxycy-
tosine (DDC) for at least one month before AIDS was
diagnosed. Protease inhibitors were not used.
CARDIAC EVENTS BEFORE AIDS DIAGNOSIS. Serious cardiac
events and any cardiac events that occurred at least one
month before AIDS diagnosis were considered as potential
predictors. Serious cardiac events included transient and
chronic congestive heart failure, hypotension, severe dys-
rhythmia, cardiac tamponade, cerebrovascular accident as-
sociated with hemodynamic instability, and cardiac arrest.
The category of “any cardiac event” included any of the
serious cardiac events, plus tachycardia, bradycardia, and
hypertension.
Definition of clinical end points. Data on rhythm abnor-
malities were extracted from echocardiographic, ECG, and
Holter monitor studies, as well as from medical records. For
all the end points except death, the cardiac event considered
was the first one occurring at least seven days after the
diagnosis of AIDS. If a cardiac end point occurred within
seven days after the diagnosis of AIDS, the patient’s data
were removed from the analyses of cardiac end points.
Serious ECG abnormalities were defined as any of the
following: supraventricular tachycardia, atrial fibrillation or
flutter, third-degree atrioventricular block, torsade de
pointes, ventricular tachycardia or fibrillation, myocardial
infarct pattern, ST- and T-wave changes consistent with
cardiac ischemia or injury, or a prolonged QTc interval,
defined as 0.48 s or longer.
Transient and chronic congestive heart failure were de-
fined by depressed left ventricular systolic function on
echocardiography (fractional shortening of 25%), in ad-
dition to clinical signs and symptoms of heart failure
necessitating anticongestive therapy for less than 30 days
(transient) or more than 30 days (chronic). Signs and
symptoms of heart failure in children include pulmonary or
peripheral edema, tachypnea, tachycardia, poor feeding,
increased liver size, and deterioration in exercise tolerance.
Echocardiographic evidence of cardiac dysfunction was
required for all diagnoses of congestive heart failure because
other illnesses associated with HIV infection may mimic the
signs and symptoms of congestive heart failure.
Cardiac tamponade was defined by echocardiographic
evidence of a marked accumulation of pericardial fluid that
was consistent with tamponade, that resulted in clinical
symptoms, and that required pericardiocentesis.
Cerebrovascular accident secondary to hemodynamic ab-
normalities was defined as either a cerebral hemorrhage or a
cerebral infarct associated with severe hypertension or hy-
potension.
Cardiorespiratory arrest was defined as the sudden onset
of hemodynamic abnormalities severe enough to require
chest compressions and pharmacologic intervention.
Death with cardiac dysfunction (cardiac death) was de-
fined as either sudden death presumed to be secondary to
dysrhythmia or as death associated with marked left ven-
tricular dysfunction within the preceding six months.
Marked left ventricular systolic dysfunction was defined by
low contractility (a stress-velocity index 2 SD below
normal) and depressed fractional shortening (25%) as
measured by echocardiography (15–17).
The predictor analyses were performed for three clinical
outcomes: serious cardiac events, all-cause mortality, and
death with cardiac dysfunction. Serious cardiac events were
as follows: transient or chronic congestive heart failure,
marked dysrhythmia, cardiac tamponade, cerebrovascular
accident associated with hemodynamic instability, or cardiac
arrest. Follow-up for clinical events ended in the summer of
1994 when the principal investigator left the study institu-
tion.
Statistical analysis. Cox proportional hazards regression
analysis was used to identify predictors of each of the three
study outcomes. All of the previously described demo-
graphic, clinical, and immunologic characteristics, mea-
sured at the time of AIDS diagnosis, were considered in
univariate analyses as potential risk factors. Risk factors
with a significance level of 0.10 or less were then included
in the final multivariable models. All of the final multi-
variable models also included CD4 counts and an indi-
cator variable for wasting because of their confounding
effects on the other predictors. A two-sided p value of
0.05 or less in the final model was considered indicative
of statistical significance.
Nineteen patients with missing CD4 counts were coded
with an indicator variable for missing data. In this way, all
of the subjects could be used for multivariable modeling, but
only those children with actual CD4 counts were used to
estimate the impact of CD4 on the end points.
Because EBV and CMV status were not available for
many children, separate analyses were performed by adding
these predictors to the final multivariable models. These
results may not be generalizable to the entire study cohort
and are considered secondary findings.
Results are presented as two-sided p values, relative risks,
and 95% confidence intervals. To illustrate the differences in
time to cardiac death between children with and without
selected identified risk factors, we used the SAS statistical
program to estimate survival curves based on the Cox
regression coefficients. A baseline survival curve is estimated
by maximal likelihood from the entire cohort, and then
modified according to the proportional hazards assumption
to the degree dictated by the regression coefficients (27).
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RESULTS
Of the 68 patients, 48 (71%) acquired HIV infection by
vertical transmission, and 20 (29%) by transfusion of blood
products (10 of these patients had hemophilia). All of the 19
patients excluded from the study acquired HIV by vertical
transmission; the only significant difference between the
vertically infected study group and the excluded children
was that males were more common in the vertically infected
study group (Table 1).
At the time of the first AIDS-defining condition, seven
patients were anemic and 22 were on antiretroviral therapy
(12 on ZDV, 7 on DDI, and 3 on DDC). Other charac-
teristics are listed in Table 2.
Cardiac events occurred in 56 (82%) patients after the
diagnosis of AIDS (Table 3). Nineteen (28%) patients
experienced a serious cardiac event after AIDS diagnosis
(Table 3). Among the 50 patients with data available before
AIDS diagnosis, 22 (44%) had a cardiac event, including 5
(10%) who had serious cardiac events.
Forty-three (63%) of the patients died during the study
period. Fifteen deaths (35%) were associated with marked
cardiac dysfunction. The estimated median survival after
AIDS diagnosis was 1.6 years. Median time to death
associated with cardiac dysfunction was 5.4 years. Fifteen of
the 43 deaths were among transfusion patients (15/20 or
75% mortality); the remaining 28 deaths were among
vertically infected study patients (28/48 or 58% mortality).
The 58% mortality in vertically infected study patients was
Table 1. Clinical Characteristics of Study and Excluded Patients at the Time of
AIDS Diagnosis
Characteristic
Study Patients No. (%)
Excluded Patients
No. (%)*
Infected by
Transfusion
(n  20)
Vertically
Infected
(n  48)
Vertically
Infected
(n  19)
Gender
Male 15 (75) 30 (62)‡ 5 (26)‡
Female 5 (25) 18 (38) 14 (74)
Race/ethnicity
White 16 (80) 16 (33) 6 (32)
Black 4 (20) 21 (44) 8 (42)
Hispanic 0 11 (23) 5 (26)
Age at AIDS diagnosis (yrs)
Median 14.5 1.4 0.9
Range 2.4 to 26.2 0.3 to 13.3 0.2 to 6.5
AIDS classification†
Encephalopathy (P-2B) 1 (5) 16 (33) 4 (21)
LIP (P-2C) 0 14 (29) 2 (11)
Opportunistic infection (P-2D1) 15 (75) 19 (40) 12 (63)
Recurrent bacterial infection (P-2D2) 3 (15) 1 (2) 1 (5)
Malignancy (P-2E) 1 (5) 0 0
Wasting 2 (10) 4 (8) 2 (11)
*No excluded patient acquired human immunodeficiency virus by transfusion. †According to 1987 criteria of the Centers for
Disease Control and Prevention (14); percentages do not add up to 100% because patients could have more than one diagnosis.
‡Significant difference between vertically transmitted study and excluded patients by Fisher exact test (p  0.01).
AIDS  acquired immunodeficiency syndrome; LIP  lymphoid interstitial pneumonitis.
Table 2. Clinical and Laboratory Characteristics of the Study
Sample at the Time of AIDS Diagnosis
Characteristic n
Median
(Minimum, Maximum)
Height (z-score) 60 1.68 (7.19, 1.72)
Weight (z-score) 63 1.53 (3.96, 2.45)
CD4 (%) 62 9.5 (0, 48)
Absolute CD4 (cells/mm3) 49 101 (0, 2,465)
CD4 (z-score) 49 2.7 (4.68, 0.41)
IgG (mg/dl) 64 1,650 (151, 9,670)
IgA (mg/dl) 63 187 (15, 1,960)
IgM (mg/dl) 64 167 (14, 746)
IgG (z-score) 64 2.88 (4.83, 11.55)
IgA (z-score) 63 1.75 (4.85, 9.68)
IgM (z-score) 64 1.45 (1.36, 3.65)
Hemoglobin (g/dl) 65 10 (6.3, 14.2)
Albumin (mg/dl) 67 3.5 (1.9, 4.7)
AIDS  acquired immunodeficiency syndrome; Ig  immunoglobulin.
Table 3. Proportion of Patients Experiencing Cardiac Events
Before and After AIDS Diagnosis
Cardiac Event
Before,
No. (%)*
(n  50)
After,
No. (%)†
(n  68)
Any cardiac event 22 (44) 56 (82)
Serious cardiac events 5 (10) 19 (28)
Transient congestive heart failure 0 5 (7)
Chronic congestive heart failure 1 (2) 10 (15)
Serious ECG abnormalities 3 (6) 8 (12)
Pericardial tamponade 0 3 (4)
Cerebrovascular accident 0 3 (4)
Cardiorespiratory arrest 1 (2) 7 (10)
*Median duration of follow-up before AIDS diagnosis, 1.1 years; range, one week to
7.4 years (18 patients had no previous follow-up). †Median time from AIDS to death
or end of follow-up, 1.0 year, range, one week to 7.9 years.
AIDS  acquired immunodeficiency syndrome; ECG  electrocardiogram.
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not different from the 53% mortality in excluded vertically
infected patients.
Clinical predictors of adverse cardiac events. Factors
univariately linked to an increased relative risk of overall
death were an earlier year of AIDS diagnosis, encephalop-
athy, and wasting (Table 4). The diagnosis of LIP and
higher CD4, IgG, or IgM z-scores were predictors of longer
survival. Factors linked with an increased relative risk of
death with cardiac dysfunction were male gender,
transfusion-acquired HIV infection, and the occurrence of a
severe cardiac event before AIDS diagnosis. High IgG and
IgM z-scores were protective for death from cardiac dys-
function. Recurrent severe bacterial infections (CDC class
P-2D2) and the occurrence of any heart abnormality before
AIDS diagnosis predicted the occurrence of serious cardiac
events after AIDS diagnosis.
For death and cardiac death, both IgG and IgM were
found to be significant on univariate testing, but both were
highly collinear. Therefore, only IgG was included in the
final models. Similarly, for predicting serious cardiac events,
encephalopathy and opportunistic infections were found to
be exclusive diagnoses in this cohort and only encephalop-
athy was entered into the model.
In multivariable analyses (Table 5), an earlier year at
AIDS diagnosis, encephalopathy, a low IgG z-score, wast-
ing, and a low age-adjusted CD4 count significantly pre-
dicted overall mortality. Male gender, a low IgG z-score,
and a low age-adjusted CD4 count predicted death with
cardiac dysfunction (Fig. 1). When IgM was substituted for
IgG, IgM was found to be significantly related to cardiac
death but not to overall mortality.
Significant multivariable predictors of serious cardiac
events were an earlier year at AIDS diagnosis, male gender,
encephalopathy, recurrent bacterial infections, and wasting
(Table 5). Opportunistic infections were not significant
when substituted for encephalopathy.
The effects of the two significant predictors, CD4 z-score
and IgG z-score, on cardiac death are shown in Figure 1.
For example, the median time to cardiac death after AIDS
diagnosis for an average patient in this cohort (with a CD4
count approximately 2 SD below normal and an IgG level 3
SD above normal) was about 3.4 years (Fig. 1, curve B). In
contrast, median time to cardiac death increases to 5.4 years
in patients whose CD4 counts are only 1 SD below normal
and whose IgG is 4 SD above normal (Fig. 1, curve A).
Conversely, median time to cardiac death falls to approxi-
mately 2.1 years for a patient with a CD4 count 3 SD below
normal and an IgG level 2 SD above normal (Fig. 1, curve
C). Male gender was a very strong predictor for death with
cardiac dysfunction; 14 of 15 patients who had this outcome
were males.
Including CMV and EBV status in the multivariable
models substantially restricted sample size, and therefore
these variables were incorporated only in the final models.
Positive CMV and EBV status were associated with in-
creased risks for most of our end points. However, statistical
significance was reached only for the impact of EBV
positivity on overall mortality (hazard ratio  4.6; 95%
Table 4. Potential Predictors of Adverse Cardiac Outcomes and Mortality by
Univariate Analysis
Predictor Mortality Cardiac Death
Serious Cardiac
Event
Year of AIDS diagnosis 0.85 [0.73, 0.98] 0.79 [0.6, 1.03] 0.81 [0.644, 1.02]
Male gender 1.62 [3.18, 0.83] 9.43 [1.23, 71.4] 3.41 [0.99, 11.76]
White race 1.75 [0.96, 3.21] 1.86 [0.7, 5.3] 1.26 [0.50, 3.22]
Infected by transfusion 1.84 [0.98, 3.48] 3.11 [1.1, 8.76] 1.8 [0.67, 4.79]
Age at diagnosis 1 year 1.43 [0.68, 3.02] 1.05 [0.26, 4.29] 0.57 [0.17, 1.95]
Encephalopathy 2.32 [1.21, 4.41] 2.7 [0.86, 8.46] 2.41 [0.87, 6.72]
LIP 0.33 [0.13, 0.84] 0.33 [0.07, 1.50] 0.99 [0.35, 2.78]
Opportunistic infections 0.98 [0.54, 1.78] 0.68 [0.24, 1.93] 0.4 [0.15, 1.06]
Recurrent bacterial infections 2.08 [0.63, 6.84] 2.17 [0.27, 17.25] 5.06 [1.09, 23.5]
Wasting 2.69 [1.02, 7.13] 3.95 [0.80, 19.38] 2.62 [0.58, 11.89]
CD4 z-score 0.58 [0.39, 0.87] 0.55 [0.27, 1.14] 0.97 [0.54, 1.75]
IgG z-score 0.81 [0.73, 0.9] 0.79 [0.66, 0.94] 0.94 [0.81, 1.08]
IgA z-score 0.95 [0.86, 1.05] 0.93 [0.79, 1.09] 0.93 [0.81, 1.06]
IgM z-score 0.68 [0.52, 0.87] 0.59 [0.37, 0.92] 0.76 [0.52, 1.14]
Anemia 0.91 [0.32, 2.56] 0.55 [0.07, 4.28] 0.76 [0.17, 3.35]
Hemoglobin 1.02 [0.84, 1.23] 1.12 [0.82, 1.53] 0.93 [0.7, 1.23]
Albumin 0.81 [0.52, 1.26] 0.8 [0.38, 1.66] 0.76 [0.39, 1.48]
EBV co-infection 1.87 [0.89, 3.93] 2.9 [0.75, 11.21] 2.2 [0.68, 7.16]
CMV co-infection 1.11 [0.6, 2.07] 1.19 [0.42, 3.35] 2.14 [0.85, 5.42]
Height z-score 1.07 [0.87, 1.32] 0.96 [0.71, 1.3] 0.98 [0.74, 1.3]
Weight z-score 1.14 [0.9, 1.44] 1.04 [0.69, 1.57] 0.98 [0.67, 1.43]
Any severe cardiac events before AIDS 1.68 [0.66, 4.3] 5.07 [1.55, 16.5] 2.31 [0.52, 10.18]
Any cardiac events before AIDS 1.7 [0.89, 3.23] 1.76 [0.55, 5.63] 2.74 [1.01, 7.44]
Data are presented as relative risk [95% confidence interval]. Covariates significant at p  0.10 are denoted in bold.
AIDS  acquired immunodeficiency syndrome; CMV  cytomegalovirus; EBV  Epstein-Barr virus; Ig  immunoglob-
ulin; LIP  lymphoid interstitial pneumonitis.
1602 Al-Attar et al. JACC Vol. 41, No. 9, 2003
Predictors of Heart Disease in Pediatric AIDS May 7, 2003:1598–605
confidence interval: [1.5, 14.0]; p 0.01, after adjusting for
all of the factors in Table 5).
Correlations with year of AIDS diagnosis. In more recent
years, vertically infected patients experienced their first
AIDS-defining condition at an older age (r  0.34, p 
0.02). AIDS diagnosis in more recent years also correlated
with a longer follow-up before AIDS diagnosis (r  0.31,
p  0.01) and a lower CD4 z score at the time of AIDS
diagnosis (r  0.32, p  0.03). However, regression
analysis indicated that patients diagnosed with AIDS in
more recent years survived longer and were less likely to
experience serious cardiac events (Table 5).
DISCUSSION
Serious cardiac events occurred frequently (28%) in pediatric
patients with AIDS. Of the 43 patients who died during the
study period, 15 (35%) died with cardiac dysfunction.
Several factors were able to predict mortality, death with
cardiac dysfunction, and serious cardiac events. After ad-
justment in multivariable models, encephalopathy and wast-
ing significantly predicted mortality and serious cardiac
events, whereas opportunistic infections as the first AIDS-
defining illness did not. This is unfortunate, as there have
been many advances in the management and prophylaxis of
opportunistic infections but not in the treatment of enceph-
alopathy and wasting. A more immunocompromised state,
marked by a lower age-adjusted CD4 count, was a signifi-
cant prognostic sign of poor survival and death with cardiac
dysfunction, corroborating results from other studies (1,8).
Also in multivariable models, a high IgG z score predicted
longer survival, and EBV co-infection predicted poorer
survival. Hypergammaglobulinemia in HIV may indicate an
immune system reaction that is not yet complete and is
perhaps a marker of less severe immunosuppression. Serum
IgG level has been identified as an immune factor that
Table 5. Multiple Regression Analysis of Predictors of Mortality and Cardiac Outcomes
Predictor Number of Events/
Number of Patients
Mortality
43/68
Cardiac Death
15/68
Serious Cardiac
Event 19/65
Year of AIDS diagnosis 0.8 [0.67, 0.97] 0.78 [0.54, 1.21] 0.76 [0.58, 0.99]
(p  0.02) (p  0.18) (p  0.042)
Male NA 16.9 [1.7, 167] 4.1 [1.02, 17]
(p  0.017) (p  0.048)
White race 0.65 [0.3, 1.5] NA NA
(p  0.32)
Transfusion acquired 0.75 [0.3, 1.9] 0.64 [0.11, 3.7] NA
(p  0.55) (p  0.61)
Encephalopathy (P-2B) 5.1 [2.1, 12.2] 5.0 [0.6, 38.4] 4.7 [1.1, 19]
(p  0.001) (p  0.12) (p  0.03)
LIP (P2C) 0.5 [0.2, 1.7] NA NA
(p  0.29)
Recurrent bacterial infections (P-2D2) NA NA 9.3 [1.3, 67]
(p  0.03)
Wasting 8.9 [2.5, 31.8] 9.7 [0.98, 97] 6.9 [1.2, 40]
(p  0.001) (p  0.052) (p  0.03)
Low CD4 z-score 2.7 [1.4, 5.3] 4.2 [1.1, 12] 1.3 [0.6, 2.7]
(p  0.002) (p  0.03) (p  0.54)
IgG z-score 0.82 [0.72, 0.94] 0.68 [0.51, 0.91] NA
(p  0.004) (p  0.008)
Any severe cardiac events before AIDS NA 0.96 [0.2, 5.9] NA
(p  0.96)
Any cardiac event before AIDS NA NA 1.6 [0.50, 5.0]
(p  0.43)
Data are presented as relative risk [95% confidence interval] (p value).
NA  did not reach p  0.10 on univariate testing and therefore was not entered in the multiple regression model. Other
abbreviations as in Table 4.
Figure 1. Survival time to death with cardiac dysfunction (“cardiac death”)
in AIDS patients. Curve B represents a typical AIDS patient in our cohort
with all of the variables included in our multiple regression model for time
to cardiac death in Table 5 set to average values. The average CD4 z-score
in our cohort was approximately 2, and the average IgG z-score was
approximately 3. Curve A represents a healthier AIDS patient with a CD4
z-score  1 and an IgG z-score  4 (all other covariates remain at
average values). Curve C represents a sicker AIDS patient with a CD4
z-score  3 and an IgG z-score  2.
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independently predicts survival in HIV-infected children
(28). Gender was a strong predictor of death with cardiac
dysfunction: 14 of 15 of these deaths were in males. In
another study in patients without HIV infection, women
with heart failure due to nonischemic causes had signifi-
cantly better survival than men with or without coronary
disease as their primary cause of heart failure, supporting the
gender-related differences in cardiac outcomes observed in
this study (29). Adverse cytokine and endotoxin cardiac
effects in children with recurrent bacterial infections may
relate to increased adverse cardiac events (30). Many studies
in primates, rodents, and cardiac biopsy have addressed
theories of AIDS cardiomyopathy (31,32). Wasting also
significantly predicted serious cardiac events. The associa-
tion may be the result of micronutrient deficiencies that
affect the heart (33–36). Encephalopathy has been previ-
ously associated with adverse cardiac outcomes in HIV-
infected children (1,5) and may relate, in part to associated
autonomic dysfunction.
Clinical and laboratory characteristics of patients at the
time of AIDS diagnosis at our hospital have changed since
the first decade of the epidemic. In more recent years,
patients have been older, have had lower CD4 counts at the
time of their first AIDS-defining illness, and have survived
longer. They have also been less likely to experience serious
cardiac events and less likely to die with cardiac dysfunction.
These changes may reflect advances in the management of
HIV-infected patients, such as prophylaxis against second-
ary infections, antiretroviral therapy, nutritional interven-
tions, and closer cardiac monitoring. The duration of
follow-up before AIDS diagnosis has also been longer in
recent years, as it has been in other studies (37). The World
Health Organization recently reported that only 5% of the
estimated five to six million people with advanced HIV
disease in developing countries are being treated with highly
active antiretrovirals, falling to 1% in sub-Saharan Africa
where nearly 1 in 11 adults are infected and women, mostly
of childbearing age, account for 58% of infections (38).
There are currently 900,000 Americans living with HIV,
and this number has increased by 50,000 since 1998, largely
because advances in treatment have controlled the infection
in many people, allowing some to live longer. However,
about half of these infected Americans have not been given
a diagnosis or treated or both. Worldwide, 42 million
people are living with HIV, including 3.2 million children
under age 15; more than 25 million have died of AIDS;
14,000 new cases of HIV infection occur every day; and 100
million people over the next eight years could become
HIV-infected. The United Nations has estimated that
AIDS will kill 68 million people over the next 20 years,
more than the number claimed by AIDS in the past 20
years, and prevention can directly impact this statistic. This
suggests that the results of our study are relevant to the
majority of HIV-infected children globally.
The findings of this study are limited by its retrospective
nature. Although all patients were examined at least every
three months, the intervals between examinations were not
equal, which may have resulted in underreporting of events
or in spurious associations. However, although the practice
of monitoring for cardiac events has increased at our
institution in recent years, we found that serious cardiac
events occurred more frequently in the earlier years. Using
the proportional hazards model presumes that risks remain
constant over time, which may not be the case in reality.
However, our results represent average associations over
time.
We studied many possible predictive variables, which
may have led to a few false positive results, but we argue that
most of our findings are biologically plausible. Other po-
tentially predictive variables such as HIV viral load were not
available during this study interval. Although most of the
excluded patients from the study were patients enrolled on
a protocol, their characteristics, except for gender, were
similar to the vertically infected patients in the study group.
In conclusion, we found that adverse cardiac events are
frequent in AIDS patients but appeared to be more frequent
in earlier years when the AIDS population was monitored
less frequently and treated less aggressively. The predictors
identified in our study, at the very least, identify children
who remain at inherent risk of death or serious cardiac
events. In addition, these predictors may help in the
management of AIDS patients by identifying patients at
high risk. Identifying these predictors highlights areas
where interventions may be most productive (13,39).
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